Catalent Inc. (CTLT)

$63.50

up-down-arrow $0.02 (0.03%)

As on 17-Dec-2024 19:26EDT

Market cap

info icon

$11,522 Mln

Revenue (TTM)

info icon

$4,422 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

3.3

Div. Yield

info icon

0 %

Catalent (CTLT) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.1 %

  • ROCEROCE information

    -11.6 %

  • Industry P/EIndustry P/E information

    26.08

  • EV/EBITDAEV/EBITDA information

    40.4

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-2.3

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    181,512,000

10 Years Aggregate

CFO

$3,000.40 Mln

EBITDA

$3,396.80 Mln

Net Profit

$1,695.70 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Catalent (CTLT)
41.3 7.4 5.6 53.1 -20.6 3.6 8.3
BSE Sensex*
-9.0 5.0 -8.1 -4.3 7.6 9.8 11.9
S&P Midcap 400#
9.1 7.1 6.1 24.5 14.2 5.9 9.6
As on 17-Dec-2024  |  *As on 05-May-2026  |  #As on 05-May-2026
Company
2023
2022
2021
2020
2019
2018
2017
Catalent (CTLT)
-0.2 -64.8 23.0 84.8 80.6 -24.0 52.4
S&P Midcap 400
14.4 -14.5 23.2 11.8 24.1 -12.4 14.5
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Catalent (CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer...  Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.  Read more

  • President, CEO & Director

    Mr. Alessandro Maselli

  • Executive Chairman of the Board

    Mr. John J. Greisch M.B.A.

  • Headquarters

    Somerset, NJ

  • Website

    https://www.catalent.com

Edit peer-selector-edit
loading...
loading...

FAQs for Catalent (CTLT)

The share price of Catalent Inc (CTLT) is $63.50 (NYSE) as of 17-Dec-2024 19:26 EDT. Catalent Inc (CTLT) has given a return of -20.62% in the last 3 years.

Since, TTM earnings of Catalent Inc (CTLT) is negative, P/E ratio is not available.
The P/B ratio of Catalent Inc (CTLT) is 3.25 times as on 17-Dec-2024, a 49 discount to its peers’ median range of 6.37 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2024
-9.87
2.86
2023
-33.83
1.69
2022
38.92
4.05
2021
31.79
4.75
2020
67.20
4.01

The 52-week high and low of Catalent Inc (CTLT) are Rs -- and Rs -- as of 05-May-2026.

Catalent Inc (CTLT) has a market capitalisation of $ 11,522 Mln as on 17-Dec-2024. As per SEBI classification, it is a Mid Cap company.

Before investing in Catalent Inc (CTLT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.